A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivat in Patients with Sickle Cell Disease
Joanna Howard, Swee Lay Thien(National Institutes of Health), Susan Morris(Agios Pharmaceuticals (United States)), Eduard J. van Beers(Utrecht University), Kevin H.M. Kuo(University Health Network), Ahmar U. Zaidi(Agios Pharmaceuticals (United States)), Abdulafeez Oluyadi(Agios Pharmaceuticals (United States)), Hui Shao(University of Louisville)
Cited by 4
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162
Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis
|Blood|2015|129
Depression, Depression Treatments, and Risk of Incident Dementia: A Prospective Cohort Study of 354,313 Participants
|Biological Psychiatry|2022|113